2m 2m 2m 2m 2m 2m 2m
APIMEDS PHARM (APUS)
NYSE
$0.89$0.00 (0.00%)
Price as of Jun 23, 2026 5:01 PM EDT- $14.3MMarket Cap
- -94.34%1-Year Change
- N/AIndustry
APIMEDS PHARM (APUS)
$0.89$0.00 (0.00%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
Income Statement | |||
Total Operating Revenue | 4.3M N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | |
Gross Profit | 4.3M N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | |
Research and Development Expense | -1.6M N/A | N/A N/A | |
Depreciation and Amortization Expense | 5,706 N/A | N/A N/A | |
Total Operating Expenses | 11.9M +834.25% | 1.3M N/A | |
Operating Profit | -11.9M +834.25% | -1.3M N/A | |
Interest Income | 107,595 +3,710.02% | 2,824 N/A | |
Interest Expense | N/A N/A | -12,608 N/A | |
Interest Income and Expense and Net | 107,595 +1,199.70% | -9,784 N/A | |
Total Nonoperating Income and Expense | 5.9M +5,245.07% | -114,895 N/A | |
Income before Taxes | -11.9M +834.25% | -1.3M N/A | |
Income Taxes | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | |
Net Income | -6.0M +331.74% | -1.4M N/A | |
Net Income from Continuing Operations Applicable to Common | -6.0M +331.74% | -1.4M N/A | |
Basic EPS and Net Income | -0.55 +205.56% | -0.18 N/A | |
Diluted EPS and Net Income | -0.55 +205.56% | -0.18 N/A | |
Basic Weighted Average Shares | 10.9M +37.68% | 7.9M N/A | |
Diluted Weighted Average Shares | 10.9M +37.68% | 7.9M N/A | |
Balance Sheet | |||
Cash and Cash Equivalents | 1.6M +47,270.62% | 3,455 N/A | |
Short-Term Investments | 2.0M N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 3.6M +105,157.74% | 3,455 N/A | |
Total Current Assets | 14.0M +106,998.56% | 13,057 N/A | |
Accumulated Depreciation | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | 51,626 N/A | N/A N/A | |
Total Long-Term Assets | 51,626 N/A | N/A N/A | |
Total Assets | 164.2M +1,257,338.43% | 13,057 N/A | |
Income Taxes Payable | N/A N/A | N/A N/A | |
Total Short-Term Debt | 7.1M +1,944.51% | 346,844 N/A | |
Total Current Liabilities | 10.7M +945.21% | 1.0M N/A | |
Total Long-Term Debt | 1.0M N/A | N/A N/A | |
Total Long-Term Liabilities | 129,454 N/A | N/A N/A | |
Total Liabilities | 10.8M +690.26% | 1.4M N/A | |
Retained Earnings | -10.4M +136.64% | -4.4M N/A | |
Total Stockholders Equity | 153.3M +11,391.18% | -1.4M N/A | |
Total Shares Outstanding | 12.6M N/A | N/A N/A | |
Cash Flow | |||
Cash from Operating Activities | -8.9M +1,116.83% | -733,526 N/A | |
Capital Expenditures | 57,333 N/A | N/A N/A | |
Cash from Investing Activities | -10.1M N/A | N/A N/A | |
Dividends Paid | N/A N/A | N/A N/A | |
Cash from Financing Activities | 20.6M +6,215.26% | 326,500 N/A | |
Financials Ratio | |||
Gross Margin | N/A N/A | N/A N/A | |
Operating Margin | -280.20% N/A | N/A N/A | |
Return on Assets | -7.31% N/A | N/A N/A | |
Return on Equity | -7.90% N/A | N/A N/A | |
Revenue Growth | N/A N/A | N/A N/A | |
Current Ratio | 1.31 N/A | N/A N/A | |
Cash Ratio | 0.15 N/A | N/A N/A | |
Debt-to-Equity Ratio | 0.05 N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.05 N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow